SDGR at a glance
Schrodinger, Inc. (SDGR, SEC CIK 1490978) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Schrodinger, Inc. (SDGR) reported revenue of $255.9 million (up 23.3% from FY2024) and a net loss of $103.3 million. Diluted EPS was -$1.41.
- As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Schrodinger, Inc. (SDGR) shares worth $1.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Abel Robert Lorne on November 11, 2026 of 1,678 shares at $34.00 per share.
- In the last 90 days, SDGR insiders reported 0 open-market purchases ($0) and 8 open-market sales ($2.8M) on Form 4, a net sale of $2.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $255.9M
- +23.3% vs prior year
- Insiders · 90 days
- 0 buys · 8 sells
- Net −$2.8M
- 13F holders
- 31 funds
- $1.1B · +1 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added AI risk: rapid regulation, data leakage, bias, and third-party intellectual-property claims affecting Bunsen and platform deployment
- Most material update, hosted-software transition: near-term revenue decline as recognition shifts from upfront on-premise sales to contract-term recognition
- Regulatory risk, clinical diversity plans: uncertainty after FDA draft guidance removal, court-ordered restoration, and unresolved marketing-application requirements
- Operational risk, AI competition: AlphaFold3, Chai-3, Boltz-2, and OpenFold could reduce demand for Schrödinger’s platform
- Financial risk, operating losses: $37.7 million quarterly net loss and $720.6 million accumulated deficit despite $373.4 million in liquidity
Management Discussion & Analysis
- Revenue $64.491M, up 19% YoY from $54.324M
- Operating loss $26.129M vs $45.947M, operating margin -40.5% vs -84.6%
- Drug discovery best segment, revenue $24.187M, up 86%; contribution worst, $2.151M, down 60%
- Cash and equivalents, restricted cash, and securities $373.4M; nine-month operating cash outflow $96.482M vs $29.992M inflow
- Near-term revenue headwind from hosted-software transition, with management expecting revenue to decline as recognition shifts over contract terms
AI summary of the SDGR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter financial results for period ended September 30, 2026 announced
- Investors should review Exhibit 99.1 for revenue, profitability, guidance and segment performance details
Item 7.01: Regulation FD Disclosure
- Company corrected ASH abstract: SGR-1505 combination study in relapsed/refractory B-cell malignancies has not started
- SGR-1505 development depends on identifying strategic partnership opportunities
Item EX-99.1: Item EX-99.1
- Q3 revenue $64.5M, up 19%, led by drug discovery revenue of $24.2M versus $13.0M
- ACV $44.7M, up 17%, with hosted software revenue up 49% to $17.2M
Item 2.02: Results of Operations and Financial Condition
- Q2 FY2026 results released August 5, 2026, covering quarter ended June 30, 2026
- Full financial results furnished in Exhibit 99.1, requiring review for revenue, profitability, and guidance
Item EX-99.1: Item EX-99.1
- Q2 revenue $58.9M, up 8%, led by drug discovery revenue $23.0M versus $13.9M
- ACV $29.6M, up 27%, while software revenue fell 10% to $32.5M amid the hosted-licensing transition
Item 7.01: Regulation FD Disclosure
- $57 million cash payment received upon Eli Lilly’s completion of Ajax Therapeutics acquisition
- Additional cash milestone payments remain possible based on Ajax clinical and regulatory achievements
AI summaries of SDGR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SDGR
Don't miss the next SDGR filing
- Alerts as it files. A push when SDGR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SDGR, by share count.
- Ask anything. An AI agent that reads every SDGR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Davie Paul Jonathan | A | Nov 11, 2026 | 18,400 | - |
| Davie Paul Jonathan | A | Nov 11, 2026 | 110,600 | - |
| Abel Robert Lorne | Sell | Nov 11, 2026 | 1,678 | $34.00 |
| Abel Robert Lorne | M | Nov 11, 2026 | 21,927 | - |
| Abel Robert Lorne | M | Nov 11, 2026 | 21,927 | $17.00 |
| Abel Robert Lorne | Sell | Nov 11, 2026 | 21,927 | $34.00 |
| Tran Yvonne | M | Nov 9, 2026 | 32,000 | $17.00 |
| Tran Yvonne | Sell | Nov 9, 2026 | 400 | $29.97 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $207.5M | $255.9M |
| Gross Profit | - | $132.1M | $142.6M |
| Operating Income | - | -$209.3M | -$166.9M |
| Net Income | - | -$187.1M | -$103.3M |
| Gross Margin | - | 63.6% | 55.7% |
| Op. Margin | - | -100.8% | -65.2% |
| Net Margin | - | -90.2% | -40.4% |
| Balance Sheet | |||
| Total Assets | $803.0M | $823.2M | $726.2M |
| Equity | - | $421.4M | $364.1M |
| ROE | - | -44.4% | -28.4% |
| Per Share | |||
| EPS | - | $-2.57 | $-1.41 |
| Cash Flow | |||
| Operating CF | - | -$157.4M | $13.9M |
| CapEx | $13.4M | $7.3M | $1.4M |
Source: XBRL data in Schrodinger, Inc. (SDGR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SDGR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 31 | $1.12B |
| Q2 2026 | 30 | $590.3M |
| Q1 2026 | 31 | $383.9M |
| Q4 2025 | 27 | $610.6M |
| Q3 2025 | 29 | $709.2M |
| Q2 2025 | 28 | $683.7M |
| Q1 2025 | 25 | $482.0M |
| Q4 2024 | 23 | $432.2M |
- ARK Investment Management+220.9K (+10%)
- Dimensional Fund Advisors+96.1K (+15%)
- Bank of America Corp+80.9K (+45%)
- Vanguard Portfolio Management LLC+67.9K (+2%)
- Morgan Stanley+48.1K (+4%)
- Citadel Advisors LLC−436.9K (-49%)
- BlackRock−231.4K (-2%)
- Goldman Sachs Group−165.3K (-23%)
- AQR Capital Management−147.4K (-8%)
- Wells Fargo & Co−35.8K (-58%)
- Millennium Management+133.8K
- Franklin Resources+100.3K
- D.E. Shaw & Co+63.7K
- Bridgewater Associates LP+12.7K
- Mangrove Partners−20.2K
- Two Sigma Investments−12.4K
- FMR LLC (Fidelity)−12.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 224 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SDGR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 21, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 17, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | May 20, 2026 | - | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SDGR SEC filings: frequently asked questions
Are SDGR insiders buying or selling?
In the last 90 days, Schrodinger, Inc. (SDGR) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $2.8 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SDGR stock?
As of September 30, 2026, the largest Schrodinger, Inc. (SDGR) holders among the 13F filers tracked by SignalX were BlackRock ($319.5 million), Gates Foundation Trust ($216.8 million), Vanguard Portfolio Management LLC ($119.7 million), Vanguard Capital Management LLC ($83.1 million), ARK Investment Management ($73.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SDGR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Schrodinger, Inc. (SDGR) reported revenue of $255.9 million (up 23.3% from FY2024) and a net loss of $103.3 million. Diluted EPS was -$1.41. The figures come from the XBRL data in the 10-K.
What did SDGR report in its latest 8-K?
Schrodinger, Inc. (SDGR) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Third-quarter financial results for period ended September 30, 2026 announced.
What are the latest SDGR SEC filings?
Schrodinger, Inc. (SDGR) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 12, 2026.
What is SDGR's SEC CIK number?
Schrodinger, Inc. (SDGR)'s SEC Central Index Key (CIK) is 1490978. EDGAR lists every SDGR filing under that number.
Ask anything about SDGR
The research agent reads SDGR's filings, financials, insider trades and 13F holders, then answers with sources.